ARTICLE | Company News
Alnylam Pharmaceuticals Inc, Alpha-1 Foundation deal
June 23, 2014 7:00 AM UTC
The foundation’s wholly owned for-profit venture subsidiary, The Alpha-1 Project (TAP), is funding an undisclosed portion of Alnylam’s development of ALN-AAT to treat alpha 1-antitrypsin (AAT; A1AT;...